FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/12/098258 [Registered on: 01/12/2025] Trial Registered Prospectively
Last Modified On: 04/02/2026
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Homeopathy 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Homoeopathic management of Muscular Soreness in Para-Sport Players 
Scientific Title of Study   Role of homoeopathic medicine in the treatment of delayed onset muscle soreness (DOMS) in para-sport players: A multicentric double-blind randomized control trial 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Harleen Kaur  
Designation  Research Officer (Hom)/S-2  
Affiliation  Central Council for Research In Homoeopathy 
Address  Central Council for Research In Homoeopathy, Room No - 313, 3rd Floor 61- 65, D Block, Institutional Area, Janakpuri
JANAKPURI
West
DELHI
110058
India 
Phone  9818709729  
Fax    
Email  dr.harleenkaur@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Harleen Kaur  
Designation  Research Officer (Hom)/S-2  
Affiliation  Central Council for Research In Homoeopathy 
Address  Central Council for Research In Homoeopathy, Room No - 313, 3rd Floor 61- 65, D Block, Institutional Area, Janakpuri
JANAKPURI
West
DELHI
110058
India 
Phone  9818709729  
Fax    
Email  dr.harleenkaur@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Harleen Kaur  
Designation  Research Officer (Hom)/S-2  
Affiliation  Central Council for Research In Homoeopathy 
Address  Central Council for Research In Homoeopathy, Room No - 313, 3rd Floor 61- 65, D Block, Institutional Area, Janakpuri
JANAKPURI
West
DELHI
110058
India 
Phone  9818709729  
Fax    
Email  dr.harleenkaur@gmail.com  
 
Source of Monetary or Material Support  
Central Council for Research in Homoeopathy 
 
Primary Sponsor  
Name  Central Council for Research In Homoeopathy 
Address  Central Council for Research in Homoeopathy, 61-65, D-Block, Institutional Area, Janakpuri, Delhi - 110058 
Type of Sponsor  Research institution 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Mr Kirubhakar Raja  Site Identified By Tamil Nadu Para Sports Association  Para Sports Department, Ground Floor, Raja Muthiah Road, Periamet, Kannappar Thidal, Choolai, Chennai - 600003 Tamil Nadu
Chennai
TAMIL NADU 
9500244444

rajavicotory68@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee, N.I.E.P.M.D., Chennai  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  Delayed Onset Muscle soreness 
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Individualized homoeopathic medicines  Homoeopathic medicines to be used in the trial are known pharmacopoeial preparations. The medicines will be administered orally in globules of Size 30. The medicine will be repeated depending on the potency and complaints of the patient in accordance with the principles of homoeopathy. Once the improvement sets in, placebo is to be continued in non-medicated globules till the medicine continues to act for 1 month. 
Comparator Agent  Placebo  The standard treatment regimen with additional identical placebo will be prescribed in the standard treatment group for 6 months. The placebo will be administered orally in non medicated globules of size 30. The Placebo will be repeated twice or thrice a day for maximum of 1 month. 
 
Inclusion Criteria  
Age From  15.00 Day(s)
Age To  40.00 Day(s)
Gender  Both 
Details  Certified Para-sports players of grass root level (non-elite level) of any Para-game and of any gender, between 15 years to 40 years of age with symptoms of DOMS.

At least 2 episodes of DOMS (as per ICD criteria M-79.6) reported in last one year.

Marked discomfort sensation in the upper or lower extremities.

Painful sensation in the upper or lower extremities.

Those who are willing to attend all monitored training sessions at the sports site during the study.

Those who are willing to perform all required physical tests on each occasion, to participate in all fasting blood sample collections.

Those who have not taken any medication (e.g., painkillers, anti-inflammatory) in the last one week, are not taking nutritional supplements with intracellular buffers that are banned or recognized as doping substances as per NADA/WADA guidelines or consumption of any other illegal substances.

Written Informed consent from the patient.
 
 
ExclusionCriteria 
Details  Participants on medications like painkillers and anti-inflammatories (NSAIDS) for last one week.

Participants on Disease-modifying ant rheumatic drugs (DMARDS) in last 6 months.

Participants having injuries that can mimic the symptoms of DOMS like fibromyalgia, rheumatoid arthritis, poliomyositis, statins-induced muscle pain etc.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Other 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
Change in functional recovery through Likert Scale and VAS in both the arms recorded daily for the first week, and then once a week for the remaining 3 weeks.
change in biomarkers, S. Creatinine kinase, S. Calcium, TNF-alpha and IL-10 (Day 0, Day 7 and Day 31).
 
1 Month 
 
Secondary Outcome  
Outcome  TimePoints 
Pre-post assessment of blood and urine samples for the presence of pre-identified salts known as doping agents, in various hematological and urological parameters, first at the beginning, then after 24 hours of starting homoeopathic medication, followed by the last sample collection after one week of repeated doses (Day 0, Day 1 and Day 7 of the recruitment).  1 Month 
 
Target Sample Size   Total Sample Size="90"
Sample Size from India="90" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   01/01/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details
Modification(s)  
N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  

Title

Role of homoeopathic medicine in the treatment of delayed onset muscle soreness (DOMS) in para-sport players: A double blind randomized control trial

 

Short Title

Homoeopathic management of Delayed Onset Muscle Soreness in Para-Sport Players

Protocol No.

Version 2

Study Design

Double Blind Randomised Controlled Trial

Proposed Study Center

To be identified

Protocol Details

Approvals:

Approved by 24th Special Committee for Clinical Research (SCCR) held on 20-21st May 2024.


Approved by 77th Scientific Advisory Board (SAB) held on 13th and 14th August 2024.

Approved by 31st Central Ethical Committee held on 18th – 19th November 2024.

Protocol No: 02

Protocol Team:

Principal Investigator: Dr. Harleen Kaur, Research Officer (H)/Scientist- 2, CCRH

Co- Principal Investigator: Dr. Divya Taneja, Research Officer (H)/Scientist- 3, CCRH

Study Mentors: Dr. Subhash Kaushik, Director General, CCRH

Protocol Writing: Dr. Harleen Kaur RO (H)/S-2, Dr. Gurpreet Singh, Senior Research Fellow (H) CCRH

Site investigators:  XXXXXXXXX

Study site: xxxxxxx

Objectives

Primary Objective: To determine the role of individualized homoeopathic treatment in the management of Delayed Onset Muscle Soreness in Para-Sports Players measured through Visual Analogue Scale (VAS) and Likert Scale.

 

Secondary Objective: To examine the change in pre and post blood and urine samples of the participants for presence of any doping agents in the samples first after 24 hours of starting homoeopathic medication, and then after one week of repeated doses (0, 1 and 7 days).  

Sample size

45 each arm; Total: 90

Inclusion Criteria

Certified Para-sports players of grass root level (non-elite level) of any Para-game and of any gender, between 15 years to 40 years of age with symptoms of DOMS.

At least 2 episodes of DOMS (as per ICD criteria M-79.6) reported in last one year:

Marked discomfort sensation in the upper or lower extremities.

Painful sensation in the upper or lower extremities.

Those who are willing to attend all monitored training sessions at the sports site during the study.

Those who are willing to perform all required physical tests on each occasion, to participate in all fasting blood sample collections.

Those who have not taken any medication (e.g., painkillers, anti-inflammatory) in the last one week, are not taking nutritional supplements with intracellular buffers  that are banned or recognized as doping substances as per NADA/WADA guidelines or consumption of any other illegal substances.

Written Informed consent from the patient.

 

Exclusion Criteria

Participants on medications like painkillers and anti-inflammatories (NSAIDS) for last one week.

Participants on Disease-modifying ant rheumatic drugs (DMARDS) in last 6 months.

Participants having injuries that can mimic the symptoms of DOMS like fibromyalgia, rheumatoid arthritis, poliomyositis, statins-induced muscle pain etc.

Study Product, dose, route

Individualized Homoeopathic medicines in varied potencies in required doses shall be prescribed to be taken orally, in addition to standard routine care in the treatment group. The standard treatment regimen with additional identical placebo will be prescribed in the standard treatment group.

Study duration; Duration of follow up

1.5 years; (1 year including enrolment and 1 month follow up, 6 months for data compilation)

Statistical Methodology

Data obtained during the study would be verified and analyzed using statistical methods adopted for comparative assessments on randomized patients, in discussion with statistical expert. Repeated measures ANOVA will be used.

Outcome measures

Primary Outcome:

Change in functional recovery through Likert Scale and VAS in both the arms recorded daily for the first week, and then once a week for the remaining 3 weeks.

Change in biomarkers, S. Creatinine kinase, S. Calcium, TNF-alpha and IL-10 (Day 0, Day 7 and Day 31).

 

Secondary Outcome: Pre-post assessment of blood and urine samples for the presence of pre-identified salts known as doping agents, in various hematological and urological parameters, first at the beginning, then after 24 hours of starting homoeopathic medication, followed by the last sample collection after one week of repeated doses (Day 0, Day 1 and Day 7 of the recruitment).

Financial Budget

Rs. 89 lacs approximately

 
Close